Clinical trials: Malignant Melanomas
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Urothelial Carcinoma, Melanoma
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR.
- Conditions
- Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
- Trial name
- NCT02986867
- Testing
- SAbR Treatment of Lesions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Melanoma
Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma
Prospective multicentric study including women aged 18 to 37 and men aged 18 to 45 during their visit to centers for the study and storage of human sperm and eggs (CECOS).
- Trial name
- MELpreserv (NCT05429138)
- Testing
- biological sampling
- Where
- 12 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Melanoma (Skin)
Gene Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Inserting the gene for interleukin-2 into a person's melanoma cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00005943
- Testing
- aldesleukin, staphylococcal enterotoxin B
- Where
- United States
- Sponsor
- University of Colorado, Denver
Melanoma
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012
This study is a phase I clinical trial aimed to determine the recommended dose of [131I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma (binding [131I]ICF01012 ).
- Trial name
- MELRIV-1 (NCT03784625)
- Testing
- [131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2), [131I]ICF01012 (therapeutic dose level 3)
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Centre Jean Perrin
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00033228
- Testing
- MKC1106-MT
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Mannkind Corporation
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating…
- Trial name
- NCT00089219
- Testing
- IFA, 6MHP, GM-CSF
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Virginia
Melanoma
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
This study is being conducted to explore the efficacy and safety of camrelizumab combined with SHR1020 in the treatment of advanced melanoma.
- Trial name
- NCT05051865
- Testing
- camrelizumab, SHR1020
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Basal Cell Carcinoma, Melanoma
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
The purpose of this study is to image skin and skin lesions with a new imaging technology called "multiwavelength and coherence confocal reflectance microscopy".
- Conditions
- Basal Cell Carcinoma, Melanoma, Non-Malignant Skin Disorders, Squamous Cell Carcinoma
- Trial name
- NCT00574392
- Testing
- Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Non Small Cell Lung Cancer
PDR001 + Panobinostat for Melanoma and NSCLC
The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer…
- Trial name
- NCT03982134
- Testing
- PDR001, Panobinostat
- Sponsor
- Muhammad Furqan
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients who have unresectable metastatic melanoma. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004148
- Testing
- recombinant vaccinia-B7.1 vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma, Lung Cancer, or Colorectal Cancer
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues.
- Trial name
- NCT05190185
- Testing
- TAA06 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Melanoma
Thalidomide and Dacarbazine for Metastatic Melanoma
The purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two drugs will also be assessed.
- Trial name
- NCT00006200
- Testing
- thalidomide, dacarbazine
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Melanoma, Skin Cancer
A Model for Genetic Susceptibility: Melanoma
The goal of this study is to find out if some people are more likely to get melanoma, a form of skin cancer, than others are. To do this we will compare people who have had more than one melanoma to people who have had only one…
- Trial name
- NCT00591500
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 4,082 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma
Immune Monitoring in Metastatic Melanoma
The mean survival time in the advanced tumor stage in the presence of distant metastases in malignant melanoma was less than 9 months until a few years ago.
- Trial name
- NCT04158544
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Regensburg
Melanoma (Skin)
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
RATIONALE: Studying samples of tissue in the laboratory from patients receiving carboplatin and paclitaxel with or without sorafenib tosylate may help doctors learn more about the effects of this treatment on cells.
- Trial name
- NCT01209299
- Testing
- DNA methylation analysis, gene expression analysis, laboratory biomarker analysis
- Volunteers
- 80 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Mucosal Melanoma, Recurrent Melanoma
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be…
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT00110019
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 219 sites in United States, Australia
- Volunteers
- 823 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision.
- Trial name
- EXCILYNT (NCT05839912)
- Testing
- Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
This is a study of a melanoma vaccine. Study participants will have melanoma that invaded deeply and spread to lymph nodes or another location.
- Trial name
- NCT00184067
- Testing
- Montanide ISA 51
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.